Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial

dc.creatorBueno Ramírez, Susan
dc.creatorAbarca Villaseca, Katia
dc.creatorGonzález Adonis, Pablo Andrés
dc.creatorGálvez Arriagada, Nicolás Marcelo Salvador
dc.creatorSoto Ramírez, Jorge Andrés
dc.creatorDuarte Peñaloza, Luisa Fernanda
dc.creatorSchultz Lombardic, Bárbara M.
dc.creatorPacheco, Gaspar A.
dc.creatorGonzález Carreño, Liliana Andrea
dc.creatorVázquez, Yaneisi
dc.creatorRíos Raggio, Mariana
dc.creatorMelo González, Felipe
dc.creatorRivera Pérez, Daniela
dc.creatorIturriaga, Carolina
dc.creatorUrzúa Acevedo, Marcela del Pilar
dc.creatorDomínguez De Landa, María Angélica
dc.creatorAndrade Parra, Catalina Andrea
dc.creatorBerríos Rojas, Roslye
dc.creatorCanedo Marroquín, Giselda
dc.creatorCovián, Camila
dc.date.accessioned2024-01-29T17:48:31Z
dc.date.accessioned2024-05-02T19:52:46Z
dc.date.available2024-01-29T17:48:31Z
dc.date.available2024-05-02T19:52:46Z
dc.date.created2024-01-29T17:48:31Z
dc.date.issued2021
dc.identifier10.1101/2021.03.31.21254494
dc.identifier1058-4838
dc.identifierhttps://doi.org/10.1101/2021.03.31.21254494
dc.identifierhttps://repositorio.uc.cl/handle/11534/81033
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9273088
dc.description.abstractThe ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. The rapid development of safe and protective vaccines against this disease is a global priority. CoronaVac is a vaccine prototype based on inactivated SARS-CoV-2, which has shown promising safety and immunogenicity profiles in pre-clinical studies and phase 1/2 trials in China. To this day, four phase 3 clinical trials are ongoing with CoronaVac in Brazil, Indonesia, Turkey, and Chile. This article reports the safety and immunogenicity results obtained in a subgroup of participants aged 18 years and older enrolled in the phase 3 Clinical Trial held in Chile.
dc.languageen
dc.rightsacceso restringido
dc.titleInterim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
dc.typepreprint


Este ítem pertenece a la siguiente institución